# ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

> **NCT06195709** · PHASE3 · RECRUITING · sponsor: **Institut Curie** · enrollment: 300 (estimated)

## Conditions studied

- Breast Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** Endocrine therapy
- **COMBINATION_PRODUCT:** Endocrine therapy combined with the local treatment of FES-negative lesions
- **COMBINATION_PRODUCT:** Chemotherapy

## Key facts

- **NCT ID:** NCT06195709
- **Lead sponsor:** Institut Curie
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-27
- **Primary completion:** 2029-09-27
- **Final completion:** 2030-09-27
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06195709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06195709, "ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06195709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*